Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.
Company profile
Ticker
MNMD, MMCWF, MMDCF
Exchange
Website
CEO
Robert Barrow
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Mind Medicine, Inc. • MindMed Discover GmbH • MindMed Pty Ltd • Healthmode, Inc. ...
MNMD stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
MindMed Reports First Quarter 2024 Financial Results and Business Updates
8 May 24
424B3
Prospectus supplement
30 Apr 24
424B3
Prospectus supplement
30 Apr 24
EFFECT
Notice of effectiveness
30 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-3
Shelf registration
2 Apr 24
8-K
MindMed Announces Voluntary Delisting from Cboe Canada
1 Apr 24
Transcripts
MNMD
Earnings call transcript
2024 Q1
8 May 24
MNMD
Earnings call transcript
2023 Q3
2 Nov 23
MNMD
Earnings call transcript
2023 Q2
3 Aug 23
MNMD
Earnings call transcript
2023 Q1
4 May 23
MNMD
Earnings call transcript
2022 Q4
9 Mar 23
MNMD
Earnings call transcript
2022 Q3
10 Nov 22
MNMD
Earnings call transcript
2022 Q2
12 Aug 22
MNMD
Earnings call transcript
2022 Q1
16 May 22
MNMD
Earnings call transcript
2021 Q4
28 Mar 22
MNMD
Earnings call transcript
2021 Q3
17 Nov 21
Latest ownership filings
4
Schond L. Greenway
26 Mar 24
4
Dan Karlin
26 Mar 24
4
Robert Barrow
26 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
SC 13G
COMMODORE CAPITAL LP
21 Mar 24
SC 13G
Deep Track Capital, LP
15 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Miri Halperin Wernli
29 Feb 24
4
Schond L. Greenway
29 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 117.70 mm | 117.70 mm | 117.70 mm | 117.70 mm | 117.70 mm | 117.70 mm |
Cash burn (monthly) | (no burn) | 3.07 mm | 7.21 mm | 7.13 mm | 5.54 mm | 4.72 mm |
Cash used (since last report) | n/a | 22.60 mm | 53.07 mm | 52.51 mm | 40.82 mm | 34.77 mm |
Cash remaining | n/a | 95.10 mm | 64.63 mm | 65.19 mm | 76.88 mm | 82.93 mm |
Runway (months of cash) | n/a | 31.0 | 9.0 | 9.1 | 13.9 | 17.6 |
Institutional ownership, Q4 2023
3.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 0 |
Closed positions | 76 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 573.37 mm |
Total shares | 2.13 mm |
Total puts | 0.00 |
Total calls | 14.90 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 1.97 mm | $0.00 |
Busey Wealth Management | 156.32 k | $572.13 mm |
Householder Group Estate & Retirement Specialist | 600.00 | $2.00 k |
Cutler | 129.00 | $0.00 |
Princeton Global Asset Management | 100.00 | $366.00 k |
Westside Investment Management | 66.00 | $242.00 k |
Allworth Financial | 66.00 | $242.00 k |
IFP Advisors | 30.00 | $110.00 k |
HighMark Wealth Management | 28.00 | $102.00 k |
TSFG | 24.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Schond L. Greenway | Common Shares | Payment of exercise | Dispose F | No | No | 9.78 | 5,560 | 54.38 k | 211,057 |
25 Mar 24 | Dan Karlin | Common Shares | Sell | Dispose S | No | Yes | 9.5 | 6,578 | 62.49 k | 358,452 |
25 Mar 24 | Robert Barrow | Common Shares | Sell | Dispose S | No | Yes | 9.5 | 16,519 | 156.93 k | 580,202 |
27 Feb 24 | Miri Halperin Wernli | Stock Option Common Shares | Grant | Acquire A | No | No | 4.98 | 125,000 | 622.50 k | 125,000 |
27 Feb 24 | Schond L. Greenway | Stock Option Common Shares | Grant | Acquire A | No | No | 4.98 | 150,000 | 747.00 k | 150,000 |
News
HC Wainwright & Co. Maintains Buy on Mind Medicine, Lowers Price Target to $35
10 May 24
Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S.
9 May 24
Mind Medicine Q1 2024 GAAP EPS $(1.14) Misses $(0.53) Estimate
8 May 24
"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment
7 May 24
Reported Saturday, MindMed Unveils Phase 2b Data Of MM120 For Generalized Anxiety Disorder At American Psychiatric Association Annual Meeting
6 May 24
Press releases
MindMed to Participate at May Investor Conferences
9 May 24
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
9 May 24
MindMed Reports First Quarter 2024 Financial Results and Business Updates
8 May 24
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
4 May 24
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
2 May 24